Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREVIT: GR2301 plus phototherapy in non-segmental vitiligo
CTR20262061Phase 2Active
- Sponsor
- Zhixiang Jintai
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GR2301 in Vitiligo, sponsored by Zhixiang Jintai. Started May 2026; status: active.
02
Drugs
GR2301
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20262061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262061.